Healthcare provider profile · identity verified

Adrian Sue, MD

Allopathic & Osteopathic Physicians|Family Medicine · MEDFORD, OR · NPI 1588724611

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Adrian Sue, MD received $28.00 in general payments during 2025 across 1 reported records.

Tactile Systems Technology Inc accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$28.00

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Tactile Systems Technology Inc	Unresolved — no canonical attribution shown	$28.00	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$28.00	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Flexitouch Plus Normalized: flexitouch plus	Device	Tactile Systems Technology Inc	$28.00	1	2025
Source payment records 2025-01-03 · Tactile Systems Technology Inc · $28.00 · Open Payments source
Nimbl Normalized: nimbl	Device	Tactile Systems Technology Inc	$28.00	1	2025
Source payment records 2025-01-03 · Tactile Systems Technology Inc · $28.00 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	664	178
Losartan Potassium	Losartan Potassium	436	106
Omeprazole	Omeprazole	418	112
Levothyroxine Sodium	Levothyroxine Sodium	399	92
Amlodipine Besylate	Amlodipine Besylate	356	100
Metoprolol Succinate	Metoprolol Succinate	257	76
Lisinopril	Lisinopril	242	61
Sertraline Hcl	Sertraline Hcl	198	50
Gabapentin	Gabapentin	191	45
Metformin Hcl	Metformin Hcl	189	51
Rosuvastatin Calcium	Rosuvastatin Calcium	180	50
Trazodone Hcl	Trazodone Hcl	175	53
Tamsulosin Hcl	Tamsulosin Hcl	172	47
Potassium Chloride	Potassium Chloride	167	42
Albuterol Sulfate Hfa	Albuterol Sulfate	165	79
Pantoprazole Sodium	Pantoprazole Sodium	144	35
Hydrochlorothiazide	Hydrochlorothiazide	137	40
Eliquis	Apixaban	129	24
Duloxetine Hcl	Duloxetine Hcl	127	32
Metformin Hcl Er	Metformin Hcl	118	33
Furosemide	Furosemide	112	34
Simvastatin	Simvastatin	112	28
Carvedilol	Carvedilol	97	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	79	24
Glimepiride	Glimepiride	71	16
Doxycycline Hyclate	Doxycycline Hyclate	70	61
Metoprolol Tartrate	Metoprolol Tartrate	70	22
Pravastatin Sodium	Pravastatin Sodium	67	19
Famotidine	Famotidine	65	24
Allopurinol	Allopurinol	64	17
Estradiol	Estradiol	62	17
Hydroxyzine Hcl	Hydroxyzine Hcl	61	19
Fluticasone Propionate	Fluticasone Propionate	58	27
Glipizide Er	Glipizide	56	11
Methocarbamol	Methocarbamol	56	26
Escitalopram Oxalate	Escitalopram Oxalate	54	12
Zolpidem Tartrate	Zolpidem Tartrate	53	11
Alendronate Sodium	Alendronate Sodium	49	11
Clopidogrel	Clopidogrel Bisulfate	49	16
Ezetimibe	Ezetimibe	48	suppressed
Alprazolam	Alprazolam	46	suppressed
Lovastatin	Lovastatin	46	12
Donepezil Hcl	Donepezil Hcl	44	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	43	suppressed
Atenolol	Atenolol	41	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	38	15
Finasteride	Finasteride	38	suppressed
Memantine Hcl	Memantine Hcl	38	suppressed
Benazepril Hcl	Benazepril Hcl	35	suppressed
Meloxicam	Meloxicam	35	20
Prednisone	Prednisone	35	26
Synthroid	Levothyroxine Sodium	35	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	35	suppressed
Spironolactone	Spironolactone	33	suppressed
Xarelto	Rivaroxaban	33	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	32	16
Propranolol Hcl Er	Propranolol Hcl	30	suppressed
Nitroglycerin	Nitroglycerin	29	17
Progesterone	Progesterone, Micronized	28	suppressed
Clonazepam	Clonazepam	27	suppressed
Farxiga	Dapagliflozin Propanediol	27	suppressed
Ketoconazole	Ketoconazole	26	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	26	suppressed
Azithromycin	Azithromycin	25	20
Bupropion Xl	Bupropion Hcl	23	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	14
Lorazepam	Lorazepam	22	suppressed
Ondansetron Odt	Ondansetron	22	suppressed
Ozempic	Semaglutide	22	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	22	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	14
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	15
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Primidone	Primidone	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	16
Buspirone Hcl	Buspirone Hcl	19	suppressed
Glipizide	Glipizide	19	suppressed
Hydralazine Hcl	Hydralazine Hcl	19	suppressed
Levetiracetam	Levetiracetam	19	suppressed
Cefdinir	Cefdinir	18	13
Celecoxib	Celecoxib	18	suppressed
Colchicine	Colchicine	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Raloxifene Hcl	Raloxifene Hcl	18	suppressed
Ibuprofen	Ibuprofen	17	suppressed
Topiramate	Topiramate	17	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Eszopiclone	Eszopiclone	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Cephalexin	Cephalexin	15	14
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Carbamazepine Er	Carbamazepine	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Midodrine Hcl	Midodrine Hcl	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Nystatin	Nystatin	13	suppressed
Risperidone	Risperidone	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Valsartan	Valsartan	13	suppressed
Vascepa	Icosapent Ethyl	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	12	suppressed
Estradiol (Once Weekly)	Estradiol	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Amiloride Hcl	Amiloride Hcl	11	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$28.00 · 1 records	Tactile Systems Technology Inc	Flexitouch Plus, Nimbl	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error